Evaluation of systemic exposure of nanoparticle suspensions subcutaneously administered to mice regarding stabilization, volume, location, concentration and size
Journal article, 2014

Different routes of administration are likely to result in very different outcomes due to different availability or plasma profile. The objective of the present study was to evaluate the pharmacokinetic profile after different subcutaneous (s.c.) administration of nanoparticle suspensions of a lipophilic compound to mice. Pharmacokinetics of the selected test compound and the effect of drug concentration, particle size, location of administration, volume given and particle stabilizers were studied. Adding PEGylated lipids or pluronic F-127 to the negatively charged surface of the nanoparticles increased the stability of the particles and the bioavailability. The in vivo studies demonstrated linear absorption kinetics for the selected model compound up to at least 500 mu mol/kg. Absorption from upper-neck resulted in different systemic exposure compared to administration in the hip. The former was preferred if a prolonged C-max was desired while the latter ensured a flat profile for approximately 24 hours. Administering the double volume (but the same dose) had no effect on the pharmacokinetics, whereas smaller particle size significantly increased the exposure.

implant

nanosuspension

sustained release

suspension

Dissolution rate

systemic exposure

poorly soluble

Author

Kalle Sigfridsson

Chalmers, Chemical and Biological Engineering

M. Palmer

AstraZeneca AB

Drug Development and Industrial Pharmacy

0363-9045 (ISSN) 1520-5762 (eISSN)

Vol. 40 10 1318-1324

Subject Categories

Pharmacology and Toxicology

DOI

10.3109/03639045.2013.817418

More information

Latest update

3/21/2018